INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,458,520 | -72.4% | 28,000 | -72.0% | 0.76% | -71.7% |
| Q4 2022 | $5,292,000 | +13.7% | 100,000 | 0.0% | 2.69% | +57.6% |
| Q3 2022 | $4,653,000 | +8.7% | 100,000 | +33.3% | 1.71% | -0.4% |
| Q2 2022 | $4,281,000 | +210.9% | 75,000 | +233.3% | 1.71% | +271.6% |
| Q1 2022 | $1,377,000 | -54.1% | 22,500 | -74.5% | 0.46% | -44.6% |
| Q1 2021 | $2,997,000 | -38.5% | 88,326 | -42.4% | 0.83% | -54.3% |
| Q4 2020 | $4,876,000 | – | 153,348 | – | 1.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |